Ming Lei

7.6k total citations · 1 hit paper
61 papers, 1.2k citations indexed

About

Ming Lei is a scholar working on Oncology, Surgery and Molecular Biology. According to data from OpenAlex, Ming Lei has authored 61 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 16 papers in Surgery and 14 papers in Molecular Biology. Recurrent topics in Ming Lei's work include Cancer Immunotherapy and Biomarkers (17 papers), Esophageal Cancer Research and Treatment (9 papers) and Gastric Cancer Management and Outcomes (8 papers). Ming Lei is often cited by papers focused on Cancer Immunotherapy and Biomarkers (17 papers), Esophageal Cancer Research and Treatment (9 papers) and Gastric Cancer Management and Outcomes (8 papers). Ming Lei collaborates with scholars based in China, United States and Canada. Ming Lei's co-authors include Fei Zhao, Weiwei Huang, Zhen Wang, Kun Xiong, Eric Van Cutsem, Jaffer A. Ajani, Markus Moehler, Yangyang Han, Thierry André and Kaoru Kondo and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Immunology and PLoS ONE.

In The Last Decade

Ming Lei

56 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142

2022 154 citations Thierry André, Sara Lonardi et al. Annals of Oncology profile →

Peers

Countries citing papers authored by Ming Lei

Since Specialization

Citations

This map shows the geographic impact of Ming Lei's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ming Lei with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ming Lei more than expected).

Fields of papers citing papers by Ming Lei

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ming Lei. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ming Lei. The network helps show where Ming Lei may publish in the future.

Co-authorship network of co-authors of Ming Lei

This figure shows the co-authorship network connecting the top 25 collaborators of Ming Lei. A scholar is included among the top collaborators of Ming Lei based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ming Lei. Ming Lei is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Prediction of Oil and Gas Well Integrity Using Well Construction Physical Parameters and Geospatial Metrics 2024 ·Energy & Fuels ·Yunpo Li, (unknown), (unknown), Loris Bernard, (unknown), Ming Lei, (unknown), (unknown), M. Alder, (unknown), (unknown), Emily Zhang, (unknown), Desirée L. Plata	0
2	First-Line Nivolumab and Relatlimab Plus Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma: The Phase II RELATIVITY-060 Study 2024 ·Journal of Clinical Oncology ·(unknown), Guillermo Méndez, Joseph Chao, Radim Němeček, Kynan Feeney, Eric Van Cutsem, Salah‐Eddin Al‐Batran, Wasat Mansoor, N. Maisey, Roberto Pazo-Cid, Matthew Burge, David Pérez-Callejo, R. William Hipkin, (unknown), Ming Lei, Hao Tang, Satyendra Suryawanshi, Ronan J. Kelly, Niall C. Tebbutt	27
3	MLK4 as an immune marker and its correlation with immune infiltration in Cervical squamous cell carcinoma and endocervical adenocarcinoma(CESC) 2023 ·PLoS ONE ·Meng Gong, (unknown), (unknown), Ming Lei, (unknown)	5
4	Association of earlier age at menopause with risk of incident dementia, brain structural indices and the potential mediators: a prospective community-based cohort study 2023 ·EClinicalMedicine ·(unknown), Jinping Cheng, (unknown), (unknown), Ying Liu, Jingru Jiang, (unknown), Baixuan He, Ming Lei, Honghong Li, Yi Li, Yongteng Xu, Yamei Tang	19
5	O-7 Adjuvant nivolumab vs placebo in resected esophageal or gastroesophageal junction cancer following neoadjuvant chemoradiotherapy: First report of comprehensive biomarker analyses from CheckMate 577 2023 ·Annals of Oncology ·Ronan J. Kelly, Markus Moehler, Jaffer A. Ajani, James C. Yao, (unknown), Thomas Zander, Eric Van Cutsem, Guillaume Piessen, Guillermo Méndez, Josephine Feliciano, Satoru Motoyama, Astrid Lièvre, Hope E. Uronis, Elena Elimova, Cecile Grootscholten, Karen Geboes, Yan Yang, (unknown), Ruslan D. Novosiadly, (unknown), Ming Lei	4
6	Triage by PAX1 and ZNF582 Methylation in Women With Cervical Intraepithelial Neoplasia Grade 3: A Multicenter Case–Control Study 2022 ·Open Forum Infectious Diseases ·Kun Fu, Ming Lei, Lisha Wu, Jingcheng Shi, (unknown), Wenqing Yang, (unknown), Yanan Kang, (unknown), Xuan Zhang, (unknown), (unknown), Yan Tian, Yu Zhang	11
7	Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials 2022 ·Journal for ImmunoTherapy of Cancer ·Yoon‐Koo Kang, Martin Reck, Paul Nghiem, Feng Yan, Gregory E. Plautz, Hye Ryun Kim, Taofeek K. Owonikoko, Narikazu Boku, Li‐Tzong Chen, Ming Lei, Han Chang, Wen Lin, Amit Roy, Akintunde Bello, Jennifer Sheng	10
8	DNA Repair Protein HELQ and XAB2 as Chemoresponse and Prognosis Biomarkers in Ascites Tumor Cells of High-Grade Serous Ovarian Cancer 2022 ·Journal of Oncology ·(unknown), (unknown), Ming Lei, Qiongqiong He, Lisha Wu, Yu Zhang	6
9	Endometrial cancer risk factors in Singapore Chinese: a prospective cohort study 2022 ·Annals of Epidemiology ·Ming Lei, Shalkar Adambekov, Robert P. Edwards, (unknown), Jian‐Min Yuan, (unknown), Samia Lopa, Faina Linkov	11
10	Association of shift work with incident dementia: a community-based cohort study 2022 ·BMC Medicine ·(unknown), (unknown), (unknown), Jingru Jiang, (unknown), Ying Liu, Baixuan He, Ming Lei, Honghong Li, Yi Li, Yongteng Xu, Yamei Tang	12
11	Association of LncRNA‐GAS5 gene polymorphisms and PBMC LncRNA‐GAS5 level with risk of systemic lupus erythematosus in Chinese population 2021 ·Journal of Cellular and Molecular Medicine ·(unknown), Yulan Lu, Huatuo Huang, Chunfang Wang, Hongcheng Luo, Guijiang Wei, Ming Lei, Tan Tan, Yan Wang, Yanyun Huang, (unknown), Yan Lan	16
12	The treatment strategy of patients with positive margins after cervical cold knife conization—A 7‐year retrospective study in China 2021 ·International Journal of Gynecology & Obstetrics ·Kun Fu, Ming Lei, Wenqing Yang, Lisha Wu, Jingcheng Shi, Yu Zhang	5
13	SO-27 Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142 2021 ·Annals of Oncology ·Thierry André, Sara Lonardi, Ka Yeung Mark Wong, Heinz‐Josef Lenz, Fabio Gelsomino, Massimo Aglietta, Michael A. Morse, Eric Van Cutsem, Ray McDermott, Andrew Hill, Michael B. Sawyer, Alain Hendlisz, Bart Neyns, Sandzhar Abdullaev, Arteid Memaj, Ming Lei, Scott Kopetz, Michael J. Overman	7
14	1381P Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): 14-month follow-up of CheckMate 577 2021 ·Annals of Oncology ·Markus Moehler, Jaffer A. Ajani, (unknown), Thomas Zander, Eric Van Cutsem, Guillaume Piessen, Guillermo Méndez, Josephine Feliciano, Satoru Motoyama, Astrid Lièvre, Hope E. Uronis, Elena Elimova, Cecile Grootscholten, Karen Geboes, (unknown), (unknown), Ming Lei, Kaoru Kondo, (unknown), Ronan J. Kelly	5
15	LBA7 Nivolumab (NIVO) plus chemotherapy (Chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 study 2021 ·Annals of Oncology ·Yelena Y. Janjigian, Jaffer A. Ajani, Markus Moehler, Marcelo Garrido, Carlos Gallardo, Lin Shen, Kensei Yamaguchi, Lucjan Wyrwicz, Tomasz Skoczylas, (unknown), (unknown), Mustapha Tehfé, Elena Elimova, (unknown), Valerie Poulart, Ming Lei, Kaoru Kondo, Kohei Shitara	20
16	Predicting Blood Concentration of Tacrolimus in Patients With Autoimmune Diseases Using Machine Learning Techniques Based on Real-World Evidence 2021 ·Frontiers in Pharmacology ·Ping Zheng, Ze Yu, Liren Li, Shiting Liu, Yan Lou, Xin Hao, Yu Peng, Ming Lei, (unknown), Zeyuan Wang, Fei Gao, Yuqing Zhang, Yilei Li	25
17	Upregulation of RIN3 induces endosomal dysfunction in Alzheimer’s disease 2020 ·Translational Neurodegeneration ·Ruinan Shen, Xiaobei Zhao, Lu He, (unknown), Wei Xu, Suzhen Lin, (unknown), Wanlin Yang, Kijung Sung, Brian Spencer, Robert A. Rissman, Ming Lei, Jianqing Ding, Chengbiao Wu	46
18	LBA6_PR Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): First results of the CheckMate 649 study 2020 ·Annals of Oncology ·Markus Moehler, Kohei Shitara, Marcelo Garrido, Pamela Salman, Lin Shen, Lucjan Wyrwicz, Kensei Yamaguchi, Tomasz Skoczylas, Arinilda Campos Bragagnoli, (unknown), Michael Schenker, Patricio Yañez, Mustapha Tehfé, Valerie Poulart, Dana Cullen, Ming Lei, Kaoru Kondo, (unknown), Jaffer A. Ajani, Yelena Y. Janjigian	139
19	Meniscus Allograft Transplantation for Discoid Lateral Meniscus: Clinical Comparison Between Discoid Lateral Meniscus and Nondiscoid Lateral Meniscus 2019 ·Wentao Zhang, (unknown), (unknown), (unknown), (unknown), Ming Lei	9
20	Pseudocyanides of sanguinarine and chelerythrine and their series of structurally simple analogues as new anticancer lead compounds: Cytotoxic activity, structure–activity relationship and apoptosis induction 2014 ·European Journal of Pharmaceutical Sciences ·Fangjun Cao, Yang Rui, Chao Lv, Qun Ma, Ming Lei, Huiling Geng, Le Zhou	33

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact